A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Relapsed/Refractory Autoimmune Diseases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing GoBroad Boren Hospital, Beijing, China
Contact: Study coordinator (Yajing Zhang) · zhangyj3@gobroadhealthcare.com · 010-83605200-857

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases

Autoimmune

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases

Autoimmune Diseases

Abroad (travel likely)RecruitingEARLY_PHASE1

Tianjin, China

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Autoimmune Diseases

Abroad (travel likely)RecruitingEARLY_PHASE1

Bengbu, China · Hefei, China

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Autoimmune Diseases

Abroad (travel likely)RecruitingPHASE1

Shanghai, China